Ahlem Mechali
Research Subjects
Ahlem Mechali has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Abdelhak Dehimi
Setif University Hospital Center, Setif Faculty of Medicine, The University of Setif 1 5 Department of Pediatrics Setif
2 shared publications - Aida Mohand Oussaid
Beni Messous University Hospital Center, Algiers Faculty of Medicine, The University of Health Sciences 3 Department of Pediatrics A Algiers
2 shared publications - Amina Saad Djaballah
Algiers University of Health Sciences 2 , Algiers
2 shared publications - Amina Salmi
Beni Messous University Hospital Center, Algiers Faculty of Medicine, The University of Health Sciences 7 Department of Pediatrics B Algiers
2 shared publications - Asmaa Abed
Beni Messous University Hospital Center 6 Department of Immunology Algiers
2 shared publications - Asmahane Ladjouze
Faculty of Medicine University of health science, Department of Paediatrics, Beni Messous teaching hospital, Algiers, Algeria, Algeria
2 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
MHC-II deficiency in a large Algerian cohort: Clinical, immunological, and genetic characterization
MHC class II (MHC-II) deficiency is a rare inborn error of immunity caused by defects in transcriptional regulators of MHC-II expression. In this study, we characterized the clinical, immunological, and molecular features of 107 patients from 98 unrelated Algerian families. Median ages at symptom onset and diagnosis were 5 and 14 mo, respectively, with pneumonia (82%) and chronic diarrhea (73%) predominating. CD4+ T cell lymphopenia occurred in 87.6% and naïve CD4+ T cell depletion in 86.0%. Among 99 genetically characterized patients, variants were identified exclusively in RFXANK (77.8%) and RFXAP (22.2%), including two predominant mutations (RFXANK c.338-25_338del and RFXAP c.368del) and four novel variants. Exploratory comparisons suggested a more severe phenotype in patients carrying RFXAP c.368del than in those carrying RFXANK c.338-25_338del. Five of seven transplanted patients survived versus 33.3% of non-transplanted patients. As the largest MHC-II deficiency cohort reported to date, this study substantially expands current knowledge of the disease and supports targeted genetic diagnosis in North African populations.
- 30 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
Open AccessMHC-II deficiency in a large Algerian cohort: Clinical, immunological, and genetic characterization
MHC class II (MHC-II) deficiency is a rare inborn error of immunity caused by defects in transcriptional regulators of MHC-II expression. In this study, we characterized the clinical, immunological, and molecular features of 107 patients from 98 unrelated Algerian families. Median ages at symptom onset and diagnosis were 5 and 14 mo, respectively, with pneumonia (82%) and chronic diarrhea (73%) predominating. CD4+ T cell lymphopenia occurred in 87.6% and naïve CD4+ T cell depletion in 86.0%. Among 99 genetically characterized patients, variants were identified exclusively in RFXANK (77.8%) and RFXAP (22.2%), including two predominant mutations (RFXANK c.338-25_338del and RFXAP c.368del) and four novel variants. Exploratory comparisons suggested a more severe phenotype in patients carrying RFXAP c.368del than in those carrying RFXANK c.338-25_338del. Five of seven transplanted patients survived versus 33.3% of non-transplanted patients. As the largest MHC-II deficiency cohort reported to date, this study substantially expands current knowledge of the disease and supports targeted genetic diagnosis in North African populations.
- Open Access
- 26 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
The genetic landscape of RAG deficiency: Novel and founder variants in a large Algerian cohort
RAG1/RAG2 deficiency causes diverse SCID phenotypes, but large, systematically characterized cohorts from North Africa remain lacking. We retrospectively characterized 128 confirmed RAG1/RAG2-deficient patients diagnosed over 14 years in Algeria, classified per PIDTC 2022 criteria. Consanguinity was high (70.3%), with RAG2 (57.0%) outnumbering RAG1 (43.0%), a reversal of patterns reported elsewhere. Classical SCID (61.0%) and Omenn syndrome (23.4%) predominated. Two candidate founder variants (RAG1 c.519del, RAG2 c.104G>T) accounted for 76.6% of genotypes, yet identical c.519del genotypes produced three discordant phenotypes. Four novel variants and four digenic/oligogenic cases broadened the molecular spectrum. Despite a short diagnostic delay, mortality was 89.1%, driven primarily by near-absent HSCT access (2.3%). This study expands the molecular and clinical spectrum of RAG deficiency in an underrepresented population, revealing a reversed RAG1/RAG2 ratio and phenotypic heterogeneity despite shared founder genotypes. These findings prioritize functional validation of uncertain-significance variants and underscore the need for NBS and expanded transplant access to translate diagnosis into survival.
- 26 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
Open AccessThe genetic landscape of RAG deficiency: Novel and founder variants in a large Algerian cohort
RAG1/RAG2 deficiency causes diverse SCID phenotypes, but large, systematically characterized cohorts from North Africa remain lacking. We retrospectively characterized 128 confirmed RAG1/RAG2-deficient patients diagnosed over 14 years in Algeria, classified per PIDTC 2022 criteria. Consanguinity was high (70.3%), with RAG2 (57.0%) outnumbering RAG1 (43.0%), a reversal of patterns reported elsewhere. Classical SCID (61.0%) and Omenn syndrome (23.4%) predominated. Two candidate founder variants (RAG1 c.519del, RAG2 c.104G>T) accounted for 76.6% of genotypes, yet identical c.519del genotypes produced three discordant phenotypes. Four novel variants and four digenic/oligogenic cases broadened the molecular spectrum. Despite a short diagnostic delay, mortality was 89.1%, driven primarily by near-absent HSCT access (2.3%). This study expands the molecular and clinical spectrum of RAG deficiency in an underrepresented population, revealing a reversed RAG1/RAG2 ratio and phenotypic heterogeneity despite shared founder genotypes. These findings prioritize functional validation of uncertain-significance variants and underscore the need for NBS and expanded transplant access to translate diagnosis into survival.